Marker Therapeutics Stock Performance
| MRKR Stock | USD 3.19 0.07 2.15% |
Marker Therapeutics has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 2.49, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Marker Therapeutics will likely underperform. Marker Therapeutics right now secures a risk of 7.33%. Please verify Marker Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Marker Therapeutics will be following its current price movements.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Marker Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating forward-looking signals, Marker Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return (1.84) | Five Day Return 8.11 | Year To Date Return (41.39) | Ten Year Return (93.16) | All Time Return (100.00) |
Last Split Factor 1:10 | Dividend Date 2016-09-16 | Last Split Date 2023-01-27 |
1 | Acquisition by Kim Anthony H. of 150512 shares of Marker Therapeutics subject to Rule 16b-3 | 09/13/2024 |
2 | Acquisition by Eansor Norman David of 14285 shares of Marker Therapeutics at 17.5 subject to Rule 16b-3 | 09/26/2024 |
3 | Omega Therapeutics stock hits 52-week low at 1.2 - Investing.com | 09/30/2024 |
4 | Acquisition by Kim Anthony H. of 160000 shares of Marker Therapeutics at 3.29 subject to Rule 16b-3 | 10/04/2024 |
5 | Acquisition by Kim Anthony H. of 160000 shares of Marker Therapeutics at 0.46 subject to Rule 16b-3 | 10/11/2024 |
6 | US Penny Stocks To Consider In October 2024 | 10/23/2024 |
7 | Marker Therapeutics Inc Q3 2024 Earnings EPS of -0.26, Revenue Surpasses Estimates at 1. ... | 11/14/2024 |
8 | Marker Therapeutics gets 2M NIH grant for MT-601 Phase 1 study - MSN | 11/22/2024 |
| Begin Period Cash Flow | 11.8 M |
Marker |
Marker Therapeutics Relative Risk vs. Return Landscape
If you would invest 350.00 in Marker Therapeutics on August 29, 2024 and sell it today you would lose (24.00) from holding Marker Therapeutics or give up 6.86% of portfolio value over 90 days. Marker Therapeutics is currently generating 0.1455% in daily expected returns and assumes 7.3258% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Marker, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Marker Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marker Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Marker Therapeutics, and traders can use it to determine the average amount a Marker Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0199
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | MRKR |
| Negative Returns |
Estimated Market Risk
| 7.33 actual daily | 65 65% of assets are less volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Marker Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Marker Therapeutics by adding it to a well-diversified portfolio.
Marker Therapeutics Fundamentals Growth
Marker Stock prices reflect investors' perceptions of the future prospects and financial health of Marker Therapeutics, and Marker Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Marker Stock performance.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.41 | ||||
| Profit Margin | (2.78) % | ||||
| Operating Margin | (1.97) % | ||||
| Current Valuation | 11.59 M | ||||
| Shares Outstanding | 8.92 M | ||||
| Price To Earning | (9.39) X | ||||
| Price To Book | 3.99 X | ||||
| Price To Sales | 7.80 X | ||||
| Revenue | 3.31 M | ||||
| Gross Profit | (17.13 M) | ||||
| EBITDA | (11.79 M) | ||||
| Net Income | (14.05 M) | ||||
| Cash And Equivalents | 18.08 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 3.07 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | 1.58 X | ||||
| Cash Flow From Operations | (16.44 M) | ||||
| Earnings Per Share | (1.07) X | ||||
| Market Capitalization | 29.09 M | ||||
| Total Asset | 17.13 M | ||||
| Retained Earnings | (436.29 M) | ||||
| Working Capital | 14.05 M | ||||
| Current Asset | 6.85 M | ||||
| Current Liabilities | 5.93 M | ||||
About Marker Therapeutics Performance
Assessing Marker Therapeutics' fundamental ratios provides investors with valuable insights into Marker Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Marker Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (31.16) | (32.72) | |
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (1.04) | (0.99) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (1.00) | (0.95) |
Things to note about Marker Therapeutics performance evaluation
Checking the ongoing alerts about Marker Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Marker Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Marker Therapeutics had very high historical volatility over the last 90 days | |
| Marker Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (17.13 M). | |
| Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Marker Therapeutics gets 2M NIH grant for MT-601 Phase 1 study - MSN |
- Analyzing Marker Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Marker Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Marker Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Marker Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Marker Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Marker Therapeutics' stock. These opinions can provide insight into Marker Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.